NO176316C - Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrrolidinderivater, samt mellomprodukt for framstilling av disse forbindelsene - Google Patents

Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrrolidinderivater, samt mellomprodukt for framstilling av disse forbindelsene

Info

Publication number
NO176316C
NO176316C NO901241A NO901241A NO176316C NO 176316 C NO176316 C NO 176316C NO 901241 A NO901241 A NO 901241A NO 901241 A NO901241 A NO 901241A NO 176316 C NO176316 C NO 176316C
Authority
NO
Norway
Prior art keywords
preparation
compounds
therapeutically active
pyrrolidine derivatives
analogous process
Prior art date
Application number
NO901241A
Other languages
English (en)
Other versions
NO901241L (no
NO901241D0 (no
NO176316B (no
Inventor
Peter Edward Cross
Alexander Roderick Mackenzie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO176316(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO901241D0 publication Critical patent/NO901241D0/no
Publication of NO901241L publication Critical patent/NO901241L/no
Publication of NO176316B publication Critical patent/NO176316B/no
Publication of NO176316C publication Critical patent/NO176316C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO901241A 1989-03-17 1990-03-16 Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrrolidinderivater, samt mellomprodukt for framstilling av disse forbindelsene NO176316C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents

Publications (4)

Publication Number Publication Date
NO901241D0 NO901241D0 (no) 1990-03-16
NO901241L NO901241L (no) 1990-09-18
NO176316B NO176316B (no) 1994-12-05
NO176316C true NO176316C (no) 1995-03-15

Family

ID=10653525

Family Applications (2)

Application Number Title Priority Date Filing Date
NO901241A NO176316C (no) 1989-03-17 1990-03-16 Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrrolidinderivater, samt mellomprodukt for framstilling av disse forbindelsene
NO2005008C NO2005008I2 (no) 1989-03-17 2005-04-01 Emselex-darifenacin kjemisk navn: 3-(S)-(-)-(1-karbamoyl-1,1-difenylmetyl)-1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜpyrrolidin

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2005008C NO2005008I2 (no) 1989-03-17 2005-04-01 Emselex-darifenacin kjemisk navn: 3-(S)-(-)-(1-karbamoyl-1,1-difenylmetyl)-1-Ä2-(2,3-dihydrobenzofuran-5-yl)etylÜpyrrolidin

Country Status (37)

Country Link
US (1) US5096890B1 (no)
EP (1) EP0388054B1 (no)
JP (2) JPH0764809B2 (no)
KR (2) KR920008166B1 (no)
CN (1) CN1023007C (no)
AT (1) ATE96783T1 (no)
AU (1) AU614224B2 (no)
BA (1) BA98300A (no)
CA (1) CA2012295C (no)
CL (1) CL2003002756A1 (no)
CY (2) CY1812A (no)
CZ (1) CZ280053B6 (no)
DD (1) DD292911A5 (no)
DE (2) DE69004302T2 (no)
DK (1) DK0388054T3 (no)
EG (1) EG18951A (no)
ES (1) ES2060020T3 (no)
FI (1) FI95573C (no)
GB (1) GB8906166D0 (no)
HK (1) HK130294A (no)
HU (2) HU217433B (no)
IE (1) IE62515B1 (no)
IL (1) IL93694A (no)
LU (1) LU91161I2 (no)
MX (1) MX9319890A (no)
MY (1) MY105527A (no)
NL (1) NL300191I2 (no)
NO (2) NO176316C (no)
NZ (1) NZ232958A (no)
PL (1) PL164136B1 (no)
PT (1) PT93443B (no)
RU (2) RU1833374C (no)
SG (1) SG143394G (no)
SK (1) SK129590A3 (no)
UA (1) UA18263A (no)
YU (1) YU47587B (no)
ZA (1) ZA901982B (no)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
JP3333878B2 (ja) * 1992-04-23 2002-10-15 メレルダウファーマスーティカルズ インコーポレイテッド セロトニン５ｈｔ２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
NZ290080A (en) * 1994-07-27 1999-04-29 Procter & Gamble Dihydrobenzo(thio)furan derivatives and pharmaceutical compositions
US5656661A (en) * 1994-07-27 1997-08-12 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
ATE235903T1 (de) * 1996-12-02 2003-04-15 Kyorin Seiyaku Kk Neue derivate von n-substituierten pyrrolidin derivaten und deren herstellungsverfahren
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US6890920B2 (en) * 2001-10-26 2005-05-10 Pharmacia & Upjohn Company Quaternary ammonium compounds
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
EP1546099B1 (en) 2002-07-08 2008-12-31 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
DE60231341D1 (de) 2002-08-23 2009-04-09 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
WO2004052857A1 (en) 2002-12-10 2004-06-24 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
WO2004056767A1 (en) * 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2004056811A1 (en) 2002-12-23 2004-07-08 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CN100406009C (zh) 2003-04-10 2008-07-30 兰贝克赛实验室有限公司 作为毒蕈碱受体拮抗剂的取代的氮杂双环己烷衍生物
WO2004089899A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
JP2006523676A (ja) * 2003-04-15 2006-10-19 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 第四級アンモニウム化合物と、その抗ムスカリン性剤としての使用
MXPA05011225A (es) * 2003-04-18 2005-12-14 Pharmacia & Upjohn Co Llc Politerapias.
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
WO2005007645A1 (en) 2003-07-11 2005-01-27 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
WO2005087763A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
JP2007528414A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
EP1746998A1 (en) * 2004-03-22 2007-01-31 Ranbaxy Laboratories, Ltd. Combination therapy for lower urinary tract symptoms
US20090221664A1 (en) 2005-10-19 2009-09-03 Abhijit Ray Pharmaceutical compositions of muscarinic receptor antagonists
US7442806B2 (en) * 2005-12-27 2008-10-28 Teva Pharmaceutical Industries Ltd. Processes for preparing darifenacin hydrobromide
AR062676A1 (es) 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
KR101495708B1 (ko) * 2007-02-23 2015-02-25 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물
WO2008126106A2 (en) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
WO2008152497A1 (en) * 2007-06-15 2008-12-18 Medichem, S.A. Method for determining enantiomeric purity of darifenacin and intermediates
US20090005431A1 (en) * 2007-06-30 2009-01-01 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
AR068322A1 (es) * 2007-07-13 2009-11-11 Medichem Sa Forma amorfa de hidrobromuro de darifenacina y procedimientos para su preparacion
CZ300895B6 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (en) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Improved process for producing darifenacin
EP2261205A4 (en) * 2008-04-02 2012-06-06 Kaneka Corp PROCESS FOR PRODUCING (S) -3- (1-CYANO-1,1-DIPHENYLMETHYL) -PYRROLIDINE
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
WO2010131054A1 (en) 2009-05-15 2010-11-18 Bradford Pharma Limited Redox drug derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
CA2796877A1 (en) 2010-04-30 2011-11-03 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
EP0228893A3 (en) * 1985-12-20 1990-01-03 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) Arylalkyl-heterocyclic amines, n-substituted by aryloxyalkyl group in allergy treatment
IL78939A (en) * 1986-01-17 1990-04-29 Robins Co Inc A H Pharmaceutical compositions containing n-substituted arylalkyl-and arylalkylene-piperidines and tetrahydropyridines and certain such novel compounds

Also Published As

Publication number Publication date
LU91161I2 (fr) 2005-06-13
HU217433B (hu) 2000-01-28
CN1023007C (zh) 1993-12-08
EP0388054A1 (en) 1990-09-19
ES2060020T3 (es) 1994-11-16
NL300191I2 (nl) 2005-08-01
IL93694A0 (en) 1990-12-23
NZ232958A (en) 1992-05-26
DD292911A5 (de) 1991-08-14
KR900014367A (ko) 1990-10-23
NO2005008I1 (en) 2005-04-11
PT93443B (pt) 1996-02-29
ZA901982B (en) 1991-10-30
IE62515B1 (en) 1995-02-08
BA98300A (bs) 2001-09-14
GB8906166D0 (en) 1989-05-04
DE122005000022I2 (de) 2006-02-02
HK130294A (en) 1994-12-02
HU901580D0 (en) 1990-06-28
CL2003002756A1 (es) 2005-02-11
UA18263A (uk) 1997-12-25
ATE96783T1 (de) 1993-11-15
CZ129590A3 (en) 1995-05-17
FI95573C (fi) 1996-02-26
EP0388054B1 (en) 1993-11-03
AU614224B2 (en) 1991-08-22
SG143394G (en) 1995-01-13
US5096890B1 (en) 1995-03-28
EG18951A (en) 1994-03-30
JPH07149640A (ja) 1995-06-13
IE900955L (en) 1990-09-17
SK278434B6 (en) 1997-05-07
CY2005005I1 (el) 2010-07-28
YU52790A (sh) 1992-07-20
CZ280053B6 (cs) 1995-10-18
MY105527A (en) 1994-10-31
US5096890A (en) 1992-03-17
FI95573B (fi) 1995-11-15
NO901241L (no) 1990-09-18
JPH0764809B2 (ja) 1995-07-12
PL164136B1 (pl) 1994-06-30
YU47587B (sh) 1995-10-24
DE69004302T2 (de) 1994-02-24
RU2015965C1 (ru) 1994-07-15
NL300191I1 (nl) 2005-07-01
CN1045580A (zh) 1990-09-26
IL93694A (en) 1994-08-26
CA2012295C (en) 1996-11-12
RU1833374C (ru) 1993-08-07
SK129590A3 (en) 1997-05-07
NO901241D0 (no) 1990-03-16
MX9319890A (es) 1993-08-01
PT93443A (pt) 1990-11-07
KR920008166B1 (ko) 1992-09-24
CY1812A (en) 1995-10-20
DK0388054T3 (da) 1993-12-06
DE69004302D1 (de) 1993-12-09
HU211640A9 (en) 1995-12-28
DE122005000022I1 (de) 2005-08-04
AU5140290A (en) 1990-09-20
CA2012295A1 (en) 1990-09-17
KR960015142B1 (ko) 1996-11-01
NO176316B (no) 1994-12-05
JPH02282360A (ja) 1990-11-19
NO2005008I2 (no) 2006-11-27
CY2005005I2 (el) 2010-07-28
HUT58313A (en) 1992-02-28
FI901333A0 (fi) 1990-03-16

Similar Documents

Publication Publication Date Title
NO176316C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrrolidinderivater, samt mellomprodukt for framstilling av disse forbindelsene
NO932607D0 (no) Piperidinderivater og anvendelse av disse
NO172340C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv 1,5-dideoxy-1,5-imino-(n-omega-methyl-caproat)-l-fucitol
FI922343A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten piperidiini- ja pyrrolidiinijohdannaisten valmistamiseksi
FI97468C (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
FI922835A0 (fi) Menetelmä terapeuttisesti aktiivisten piperidiinijohdannaisten valmistamiseksi
EP0903346A4 (no)
CA2069931A1 (en) Muscarinic receptor antagonists

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7, 14, 28, 49, 56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7, 14, 28, 49, 56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG. NO/DATE: 04/294/1-12 20041022

Spc suppl protection certif: 2005008

Filing date: 20050401

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: EMSELEX (7,5 MG DEPOTTABLETT MED 7, 14, 28, 49, 56 OG 98 TABLETTER I BLISTERPAKNING OG 15 MG DEPOTTABLETT MED 7, 14, 28, 49, 56 OG 98 TABLETTER I BLISTERPAKNING); NAT. REG. NO/DATE: 04/294/1-12 20041022

Spc suppl protection certif: 2005008

Filing date: 20050401

Extension date: 20150316

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2005008

Effective date: 20150316